The Impact of Docosahexaenoic Acid on the Prevention of Necrotizing Enterocolitis in Preterm Neonates

Ain Shams University60 enrolled

Overview

The study will assess the efficacy of Docosahexaenoic Acid in reducing the incidence of necrotizing enterocolitis in premature infants.

The efficacy of Docosahexaenoic Acid in reducing the incidence of necrotizing enterocolitis in preterm neonates will be evalutaed through measuring its immune-modulatory effect on proinflammatory cytokines.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

Conditions

Necrotizing Enterocolitis

Interventions

Docosahexaenoic AcidDIETARY_SUPPLEMENT

100 milligrams of Docosahexaenoic Acid

placeboOTHER

placebo

Eligibility

Sex: ALLMin age: 1 DayMax age: 3 Weeks

Medical Language ↔ Plain English

Inclusion Criteria: * Preterm neonates having a gestational age equal or less than 34 weeks at birth. * Weight (less than or equal 1.500 KG) * Clinically stable to begin enteral feeding Exclusion Criteria: * Persistent bleeding at any level. * Receiving medication to avoid coagulation. * Persistent vomiting. * Gastrointestinal malformations. * Mother taking Omega-3 supplements and planning to breastfeed.

Outcomes

Primary Outcomes

Efficacy of Docosahexaenoic Acid in reducing the incidence of Necrotizing Enterocolitis in premature infants.

Monitoring the change in the serum levels of Interleukin-1 beta

Time frame: 10 days

Central Contacts

Dina Abou El Fadl, Msc.

CONTACT

201005442855 dkhaled69@gmail.com

Yasmine Farid, MD

CONTACT

201001449558 Yasmin_Aly_Farid@hotmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.